Form 4: Cingulate EVP Raul Silva Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Cingulate Inc. EVP and CSO Raul Silva was granted 3,422 stock options as part of his employment agreement.
Summary
- Raul R. Silva, EVP and CSO of Cingulate Inc., received a grant of 3,422 stock options.
- The options have an exercise price of $6.21 per share.
- The grant was issued on March 31, 2026, and expires on March 31, 2036.
- The transaction was executed pursuant to the terms of Dr. Silva's existing employment agreement.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation with no immediate impact on company operations or financial health.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Minor dilution of existing shareholders due to the issuance of new derivative securities.
Risks
- Market volatility affecting the value of the granted options.
- The exercise price of $6.21 may be subject to future market fluctuations.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an executive equity grant.
Management Comments
- The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.
Industry Context
StockSavvy.ai notes that equity grants to C-suite executives are standard corporate governance practices intended to incentivize performance and retain key leadership within the biotechnology and pharmaceutical sectors.
Comparison to Industry Standards
- The grant follows standard industry practices for executive compensation packages in small-cap biotech firms.
- The 10-year expiration term is consistent with standard equity incentive plan structures.
Stakeholder Impact
- Minor dilution for existing shareholders upon potential future exercise of options.
Next Steps
- Reporting person may exercise options starting March 31, 2026, subject to vesting and company policy.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of the stock option grant transaction. |
| 03/31/2036 | Expiration date of the granted stock options. |
| 05/08/2026 | Date the Form 4 was signed and filed. |
Keywords
Cingulate, CING, Form 4, Insider Trading, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.